Held by 5 specialist biotech funds
High Convergence# Signal Note: Driehaus Capital Initiates $86M Position in Scholar Rock Driehaus's $86M entry into SRRK signals conviction in the company's lead program, SRK-181 (a myostatin inhibitor for spinal muscular atrophy), which is progressing through late-stage development with potential catalysts including Phase 2b data and regulatory interactions over the next 12-18 months.
AI analyst context — unlock full analysis
# Signal Note: Redmile Initiates $230M Position in SRRK Redmile Group's $230M entry into Scholar Rock signals conviction in the biotech's lead program, SRK-181, a myostatin inhibitor in Phase 2 for spinal muscular atrophy (SMA) and other neuromuscular indications. The timing suggests positioning ahead of near-term data readouts, likely including Phase 2 SMA interim or top-line results expected in 2024-2025. Given Redmile's track record in clinical-stage healthcare bets, this represents meaningful institutional validation but carries execution risk tied to efficacy and safety outcomes in a competitive muscle-wasting space.
+ 3 more positions with dollar amounts and AI context
Unlock All — 7-Day Free Trial